Cue Health

Cue Health, Inc. is a healthcare technology company that puts consumers in control of their health information and places diagnostic information at the center of care. It enables people to manage their health through real-time, actionable, and connected health information, offering individuals and their healthcare providers easy access to lab-quality diagnostics anywhere, anytime, in a device that fits in the palm of the hand. The firms first-of-its-kind COVID-19 test was the first FDA-authorized molecular diagnostic test for at-home and over-the-counter use without a prescription and physician supervision. The company was founded by Ayub Khattak and Clint Sever in 2010 and is headquartered in San Diego, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Nobilis Health Corp. engages in the operation and development of outpatient surgery centers. The firm owns and manages ambulatory and acute care facilities to deliver innovative surgical services. It operates through Medical Services and Marketing Services segment. The Medical Services segment provides the operation of hospitals, outpatient facilities, and other various related health care services. The Marketing Services segment provides marketing services, patient education services, and patient care coordination management services. The company was founded on March 16, 2007 and is headquartered in Houston, TX.

Cue Health Inc. (HLTH) delivered earnings and revenue surprises of 21.82% and 19.92%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Cue Health Inc. (HLTH) Reports Q3 Loss, Tops Revenue Estimates

SAN DIEGO--(BUSINESS WIRE)--Cue Health Inc. ("Cue") (Nasdaq: HLTH), a healthcare technology company, today reported financial results for the third quarter of 2022.

Cue Health Reports Third Quarter 2022 Results

Cue Health Inc. (HLTH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Cue Health Inc. (HLTH) Upgraded to Buy: Here's Why

SAN DIEGO--(BUSINESS WIRE)--Cue Health Inc. (“Cue”) (Nasdaq: HLTH), a healthcare technology company, announced today that it will release its third quarter 2022 financial results on Wednesday, November 9, 2022.

Cue Health to Announce Third Quarter 2022 Financial Results

Jamie-Lynn Sigler and Cue Health Announce Product Donation to Multiple Sclerosis Association of America SAN DIEGO , Oct. 6, 2022 /PRNewswire/ -- Cue Health Inc. (Nasdaq: HLTH), a healthcare technology company, has partnered with actress Jamie-Lynn Sigler, the actress best known for her roles on The Sopranos and ABC's Big Sky, to build awareness for its new Cue Care™ test-to-treatment service. With Cue Care, people who test positive for COVID-19 on any test, including antigen, can consult virtually and on-demand with a healthcare professional and easily access same-day prescription treatment delivered to their home all through the Cue Health App 1.

Cue Health Partners with Actress Jamie-Lynn Sigler to Raise Awareness of At-Home, Same-Day Test-to-Treatment Platform for COVID-19 and Beyond

SAN DIEGO , Sept. 27, 2022 /PRNewswire/ -- Cue Health Inc. ("Cue") (Nasdaq: HLTH), a healthcare technology company, today announced that it has appointed Suzanne Stone as its new Chief Commercial Officer.

Cue Health Appoints Suzanne Stone as New Chief Commercial Officer

Cue Health went public in September 2021, raising approximately $200 million in an IPO. The firm provides a COVID-19 molecular test and related software platform and is pursuing additional diagnostic tests for wide use.

Cue Health Needs Success In Flu Diagnostic To Reignite Growth

Dr. Tsay Brings Two Decades of Expertise in Clinical Medicine, Research, and Health Technology to Cue SAN DIEGO , Sept. 8, 2022 /PRNewswire/ -- Cue Health Inc. ("Cue") (Nasdaq: HLTH), a healthcare technology company, today announced that it has appointed David Tsay, MD, PhD, as its Chief Medical Officer.

Cue Health Appoints David Tsay, MD, PhD, as Chief Medical Officer

SAN DIEGO , Sept. 1, 2022 /PRNewswire/ -- Cue Health ("Cue") (Nasdaq: HLTH) today announced that it has made a de novo submission to the U.S. Food and Drug Administration (FDA) for full clearance of the Cue® Flu Molecular Test for at-home and point-of-care (POC) use.

Cue Health Makes De Novo Submission to FDA for Full Clearance of its Cue® Flu Molecular Test

SAN DIEGO--(BUSINESS WIRE)--Cue Health (“Cue”) (Nasdaq: HLTH), a healthcare technology company, announced today that its management team will present at the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13, 2022 at 4:40 p.m. Eastern Time in New York, NY. The live audio webcast and replay of the presentation may be accessed for 180 days on the “Investor Relations” section of the company's website at: www.cuehealth.com. About Cue Health Cue Health (Nasdaq: HLTH) is

Cue Health to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

SAN DIEGO , Aug. 29, 2022 /PRNewswire/ -- Cue Health Inc. (Nasdaq: HLTH), a healthcare technology company that puts diagnostic information at the center of care, today announced the nationwide launch of Cue Care™ , its same-day, at-home, test-to-treatment solution. Patients in any of the 50 states who test positive using Cue's COVID-19 tests can now use the Cue Health App to: Consult virtually and on-demand with a healthcare professional about their test result;  Obtain an e-prescription - if medically indicated - for a medication to treat the virus; and Get the medication delivered - usually within hours* - conveniently and safely at home or the medication will be made available for pickup at their local pharmacy.

Cue Health Launches Cue Care™ Nationwide to Provide Same-Day, At-Home, Test-to-Treatment Service for COVID-19

SAN DIEGO , Aug. 24, 2022 /PRNewswire/ -- Cue Health Inc. ("Cue") (Nasdaq: HLTH), a healthcare technology company, today announced a new collaboration with Fresenius Kidney Care to provide the most accurate* COVID-19 self-test to certain patients and clinical care teams. People who are immunocompromised have been disproportionately affected by COVID-19 throughout the pandemic and remain highly dependent on measures that reduce the likelihood of infections, including vaccination.

Cue Health Provides Enhanced Care & Protection for Immunocompromised Populations & Clinical Care Teams at Fresenius Kidney Care

In largest-of-its-kind clinical study on asymptomatic people, Cue demonstrated 99.4% accuracy compared to lab-based PCR SAN DIEGO, Calif. , Aug. 17, 2022 /PRNewswire/ -- Cue Health Inc. ("Cue") (Nasdaq: HLTH) announced today the preprint publication of an independent clinical study - the largest of its kind on asymptomatic people - demonstrating that its point of care (POC) molecular COVID-19 test, which produces results in approximately 20 minutes, is as accurate as a centralized lab-based RT-PCR.

Independent Study Shows Cue Health's Molecular COVID-19 Test is as Accurate as a Lab-Based PCR Test

Cue Health Inc. (NASDAQ:HLTH ) Q2 2022 Results Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Lorna Williams - Investor Relations Ayub Khattak - Chairman and Chief Executive Officer John Gallagher - Chief Financial Officer Conference Call Participants Charles Rhyee - Cowen and Company David Delahunt - Goldman Sachs Vidyun Bais - BTIG Neel Ram - Morgan Stanley Operator Welcome to Cue Health's Second Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Cue Health Inc. (HLTH) CEO Ayub Khattak Q2 2022 Results - Earnings Call Transcript

SAN DIEGO--(BUSINESS WIRE)--Cue Health Inc. ("Cue") (Nasdaq: HLTH), a healthcare technology company, today reported financial results for the second quarter of 2022. Recent Highlights Revenue of $87.7 million in the second quarter of 2022 exceeds guidance with stronger than anticipated ordering from existing customers 250,000+ Cue Readers shipped through the end of the second quarter of 2022 Flu standalone clinical studies completed and preparations are underway for a de novo submission to the

Cue Health Reports Second Quarter 2022 Results

SAN DIEGO--(BUSINESS WIRE)--Cue Health (“Cue”) (Nasdaq: HLTH), a healthcare technology company, announced today that its management team will participate at the 7th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference on Tuesday, August 16, 2022. About Cue Health Cue is a healthcare technology company that makes it easy for individuals to access health information and places diagnostic information at the center of care. Cue enables people to manage their health through real-time, act

Cue Health to Participate at the 7th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference

SAN DIEGO--(BUSINESS WIRE)--Cue Health Inc. (“Cue”) (Nasdaq: HLTH), a healthcare technology company, announced today that it will release its second quarter 2022 financial results on Wednesday, August 10, 2022. In conjunction with the release, Cue will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. To access the live call via telephone, please register in advance using the link here. Upon reg

Cue Health to Announce Second Quarter 2022 Financial Results

Seasoned Leader Brings Extensive Experience in Building Diverse, Inclusive Healthcare Organizations SAN DIEGO , July 13, 2022 /PRNewswire/ -- Cue Health Inc. ("Cue") (Nasdaq: HLTH), a health technology company, today announced that it has appointed Allison Blackwell as Chief Human Resources Officer, effective immediately. Blackwell will be responsible for leading the strategic direction of Cue's human resources function to support the overall goals of the company.

Cue Health Appoints Allison Blackwell Chief Human Resources Officer

Cue Health Inc. (NASDAQ:HLTH ) Q1 2022 Earnings Conference Call May 11, 2022 4:30 PM ET Company Participants Ayub Khattak - Chairman and Chief Executive Officer John Gallagher - Chief Financial Officer Caroline Corner - Investor Relations Conference Call Participants Neel Ram - Morgan Stanley David Delahunt - Goldman Sachs Operator Good day and welcome to Cue Health's First Quarter 2022 Earnings Call. At this time, all participants are in a listen-only mode.

Cue Health Inc. (HLTH) CEO Ayub Khattak Q1 2021 Results - Earnings Call Transcript

SAN DIEGO--(BUSINESS WIRE)--Cue Health Inc. (Nasdaq: HLTH), a healthcare technology company, (“Cue") today reported financial results for the first quarter of 2022. Recent Highlights Revenue of $179.4 million in the first quarter of 2022, compared to $64.5 million in the first quarter of 2021 235,000+ Cue Readers shipped through the end of the first quarter of 2022, including 72,000+ in the quarter Cue Covid-19 Test de novo submission to the U.S. Food and Drug Administration (FDA) for full clea

Cue Health Reports First Quarter 2022 Results

SAN DIEGO , May 2, 2022 /PRNewswire/ -- Cue Health ("Cue") (Nasdaq: HLTH) today became the first company to submit to the U.S. Food and Drug Administration (FDA) for full clearance of its molecular COVID-19 test for at-home and point-of-care use. FDA clearance would provide the public with a molecular COVID-19 test that has been fully reviewed by the FDA for safety and effectiveness.

Cue Health Makes De Novo Submission to FDA for Full Clearance of Its Molecular COVID-19 Test

SAN DIEGO--(BUSINESS WIRE)--Cue Health (“Cue”) (Nasdaq: HLTH), a healthcare technology company, announced today that it will release its first quarter 2022 financial results on Wednesday, May 11, 2022. In conjunction with the release, Cue will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the live call via telephone by dialing (888) 708-0136 for domestic callers

Cue Health to Announce First Quarter 2022 Financial Results

It wasn't related to any major development or adverse financial information.

Cue Health's Stock Dropped 38% in a Month. Here's Why That Doesn't Matter

Cue Health debuts Cue Clinic™ dashboard to give healthcare providers more choice and control over patient care as part of BioReference's product offering SAN DIEGO and ELMWOOD PARK, N.J. , April 5, 2022 /PRNewswire/ -- Cue Health Inc. ("Cue") (Nasdaq: HLTH), the healthcare technology company behind one of the country's most accurate COVID-19 tests and BioReference Laboratories, Inc., an OPKO Health company ("BioReference"), today announced that Cue is now an available point-of-care solution for BioReference's clinical customers, including for healthcare providers and point-of-care clinics in the U.S. Cue's innovative Cue Clinic™ provider dashboard will be the keystone product offered through BioReference.

Cue Health and BioReference Laboratories Bring Point-of-Care Solutions to the Clinical Setting

Cue Health Inc (NASDAQ: HLTH) reported Q4 sales of $192.5 million, compared to $13.3 million in Q4 FY20, beating the consensus of $185.29 million. The growth was driven by production capacity ramp through 2021, U.S. Department of Defense contract delivery, and expansion of customer base.

News for Cue Health Stock (HLTH)